tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio
PremiumRatingsAnalyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio
9d ago
Revolution Medicines price target raised to $182 from $165 at RBC Capital
Premium
The Fly
Revolution Medicines price target raised to $182 from $165 at RBC Capital
9d ago
Wedbush reiterates Outperform on Revolution Medicines after ASCO data
Premium
The Fly
Wedbush reiterates Outperform on Revolution Medicines after ASCO data
10d ago
Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer
PremiumRatingsMichael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer
10d ago
Revolution Medicines announces results from Phase 3 RASolute 302 trial
Premium
The Fly
Revolution Medicines announces results from Phase 3 RASolute 302 trial
11d ago
Bernstein starts Revolution Medicines at Market Perform, says upside baked in
Premium
The Fly
Bernstein starts Revolution Medicines at Market Perform, says upside baked in
21d ago
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
PremiumCompany AnnouncementsRevolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
1M ago
Revolution Medicines Signals Breakout With RAS Wins
Premium
Company Announcements
Revolution Medicines Signals Breakout With RAS Wins
1M ago
Revolution Medicines price target raised to $185 from $170 at BofA
Premium
The Fly
Revolution Medicines price target raised to $185 from $170 at BofA
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100